drugset / Trial / NCT04129775
OTO-413 in Subjects With Speech-in-Noise Hearing Impairment
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, and exploratory efficacy of OTO-413 administered as an intratympanic injection for the treatment of speech-in-noise hearing impairment.
Timeline
- Start
- 2019-10-01
- Primary completion
- 2022-09-05
- Completion
- 2022-09-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RECOMBINANT METHIONYL HUMAN BRAIN-DERIVED NEUROTROPHIC FACTOR | Unknown | — | Other |